Mouse (i.e., Mus) Patents (Class 435/354)
-
Publication number: 20130183761Abstract: The invention relates to a nucleic acid comprising a nucleotide sequence encoding a tRNA orthogonal to a eukaryotic cell, said nucleotide sequence operably linked to a promoter capable of directing transcription by eukaryotic RNA polymerase III. The invention also relates to methods for incorporating unnatural amino acids in eukaryotic cells using same.Type: ApplicationFiled: September 23, 2011Publication date: July 18, 2013Applicants: North Carolina State University, Medical Research CouncilInventors: Jason Chin, Alexandre Deiters, Rajendra Uprety, Susan M. Hancock, Sebastian Greiss
-
Publication number: 20130183274Abstract: Various embodiments of the present invention include compositions, materials and methods for maintaining and propagating mammalian mesenchymal stem cells in an undifferentiated state in the absence of feeder cells and applications of the same.Type: ApplicationFiled: February 8, 2013Publication date: July 18, 2013Applicants: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSASInventors: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIR
-
Publication number: 20130183714Abstract: The present invention relates to a method for culturing mammalian cells in a culture medium which is transferrin free and which contains no lipophilic or synthetic nitrogen-containing chelators. Also provided is the use of the medium and a process for providing a mammalian product by culturing cells capable of producing the product in the medium.Type: ApplicationFiled: December 20, 2012Publication date: July 18, 2013Applicant: Medimmune LimitedInventors: Matthew David Osborne, Jonathan H. Dempsey
-
Publication number: 20130177929Abstract: The present invention relates to a new three-dimensional co-culture method of podocytes and endothelial cells, and a relative co-culture system. Furthermore, the invention relates to the use of said co-culture system as an in vitro study model of pathologies affecting the kidneys, and in particular the renal glomerular filtration barrier.Type: ApplicationFiled: December 16, 2010Publication date: July 11, 2013Applicant: FONDAZIONE IRCCS CA' GRANDA-OSPENDALE MAGGIORE POLICLINICOInventors: Maria Pia Rastaldi, Min Li
-
Patent number: 8481318Abstract: Hair follicle stem cells are isolated in a method which relies on the identification of stem cells as being small, spindle, oval or round shaped nestin-expressing cells that are located in the permanent upper part of telogen hair follicles below the sebaceous glands and in the bulge area.Type: GrantFiled: January 26, 2010Date of Patent: July 9, 2013Assignee: Anticancer, Inc.Inventors: Lingna Li, Meng Yang
-
Publication number: 20130171157Abstract: Disclosed are NgR proteins and biologically active Nogo (ligand) protein fragments. Also disclosed are compositions and methods for modulating the expression or activity of the Nogo and NgR protein. Also disclosed are peptides which block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease.Type: ApplicationFiled: March 7, 2013Publication date: July 4, 2013Applicant: YALE UNIVERSITYInventor: YALE UNIVERSITY
-
Publication number: 20130174284Abstract: The present invention relates to a recombinant vector and a transgenic mouse for expressing human ferritin in a tissue non-specific manner, and more particularly, to a vector prepared by operably linking a human ferritin gene to a promoter including a cytomegalovirus (CMV) early enhancer element and a ?-actin promoter, and a transgenic mouse expressing human ferritin in a tissue non-specific manner, which is transformed with the vector. Further, the present invention relates to a method for preparing a transgenic mouse, and a method for monitoring cell or tissue therapy using the transgenic mouse.Type: ApplicationFiled: July 7, 2011Publication date: July 4, 2013Applicant: SNU R&DB FOUNDATIONInventors: Woo Kyung Moon, Hoe Suk Kim
-
Publication number: 20130171627Abstract: Disclosed are embryonic stem cell-derived dendritic cells, genetically modified immature dendritic cells capable of maturation, as well as methods for the production of such cells. In one embodiment, the cells made be produced by a method comprising the steps of providing a population of embryonic stem cells; culturing the embryonic stem cells in the presence of a cytokine or combination of cytokines which brings about differentiation of the embryonic stem cells into dendritic cells; and recovering the dendritic cells from the culture. In a further embodiment, the cells may be genetically modified.Type: ApplicationFiled: June 29, 2012Publication date: July 4, 2013Inventors: Herman WALDMANN, Paul J. FAIRCHILD, Richard GARDNER, Frances BROOK
-
Publication number: 20130171714Abstract: This invention relates to industrial production of proteins. More specifically, the invention relates to the res-DHFR surrogate marker, which corresponds to a fusion between DHFR and a protein conferring resistance to a toxic compound or conferring a metabolic advantage. The invention further relates to the use of res-DHFR for screening cells for high expression of a protein of interest. The invention is illustrated by the Puro-DHFR surrogate marker, which corresponds to a fusion between the puromycin N-acetyltransferase and dihydrofolate reductase (DHFR).Type: ApplicationFiled: January 16, 2013Publication date: July 4, 2013Applicant: MERCK SERONO SAInventor: MERCK SERONO SA
-
Publication number: 20130174289Abstract: The invention relates to methods to identify new SLC41A1 functions at the cell, tissue, organ and organism level. In part, it is related to methods useful in (a) identifying molecules that bind SLC41A1 polypeptides, which (b) modulate SLC41A1 related Na+/Mg2+ exchanger activity or its cellular or tissue specific expression. Thus, the invention comprises SLC41A1 mutation libraries, SLC41A1 specific antibodies, their generation and finding as well as an inducible conditional SLC41A1 knock out mice model and inducible conditional knock out SLC41A1 cell lines.Type: ApplicationFiled: September 15, 2011Publication date: July 4, 2013Applicant: FBN - Leibnitz-Institut fur NutztierbiologieInventors: Monika Schweigel, Martin Kolisek
-
Publication number: 20130164839Abstract: The present invention is directed to providing a method for culturing cells in a system containing laminin-5. The method of the present invention is characterized by a culture system containing a polypeptide selected from a group consisting of: a protein in blood other than extracellular matrix proteins, which is, serum, serum albumin, prealbumin, immunoglobulin, ?-globulin, ?-globulin, ?1-antitrypsin (?1-AT), heptoglobin (Hp), ?2-macroglobulin (?2-M), ?-fetoprotein (AFP), transferrin, retinol-binding protein (RBP) or adiponectin; gelatin; a protein belonging to a tumor necrosis factor (TNF) family; and peptone.Type: ApplicationFiled: March 31, 2011Publication date: June 27, 2013Applicant: ORIENTAL YEAST CO., LTD.Inventors: Hisataka Yasuda, Munehiro Yamada, Yukiko Taketani, Yoshiya Tomimori, Kaoru Mori
-
Publication number: 20130164306Abstract: Ligand-specific HVEM variants, compositions comprising such variants, and methods of treating inflammatory diseases comprising administering such variants, are provided.Type: ApplicationFiled: November 15, 2012Publication date: June 27, 2013Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTEInventor: SANFORD-BURNHAM MEDICAL RESEARCH IN
-
Publication number: 20130164219Abstract: The present invention relates to the identification and functional characterization of human cell-penetrating peptides (CPPs) and their use; in particular as transfection vehicles.Type: ApplicationFiled: December 12, 2012Publication date: June 27, 2013Applicant: HOFFMANN-LA ROCHE INC.Inventor: Hoffmann-La Roche Inc.
-
Publication number: 20130164785Abstract: Disclosed herein are methods and compositions for inactivating a glutamine synthetase (GS) gene, using fusion proteins comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.Type: ApplicationFiled: September 6, 2012Publication date: June 27, 2013Inventors: Pei-Qi Liu, Jeffrey C. Miller
-
Publication number: 20130157357Abstract: The invention relates to an immunogenic composition comprising a recombinant vector characterized in that it comprises a polynucleotide comprising the cis-acting central initiation region (cPPT) and the cis-acting termination region (CTS), these regions being of retroviral or retroviral-like origin, said vector comprising in addition a defined nucleotide sequence (transgene or sequence of interest) and regulatory signals of retrotranscription, expression and encapsidation of retroviral or retroviral-like origin, wherein the composition is capable of inducing or of stimulating a cell-mediated response for instance a CTL (Cytotoxic T Lymphocytes) response or a CD4 response, against one or several epitopes encoded by the transgene sequence present in the vector.Type: ApplicationFiled: December 12, 2012Publication date: June 20, 2013Applicants: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALEInventors: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, CENTRE NATIONAL DE LA RECHERCHE SCIEN
-
Publication number: 20130157308Abstract: A bidirectional expression vector is described that can be utilized to determine the existence and characteristics of bidirectional promoters. The bidirectional expression vector includes two different reporter genes in a head to head (5? to 5?) arrangement. In addition, the bidirectional expression vector can include a polylinker region located between the heads of the two reporter genes that provides multiple cloning sites for nonexclusive examination of polynucleotide sequences. The vector can also include a splicing site and drug resistance. The bidirectional expression vector can be used to examine a polynucleotide sequence for the presence of divergent regulator regions and, following determination of a bidirectional promoter, can be utilized to further elucidate characteristics of the bidirectional promoter.Type: ApplicationFiled: December 13, 2012Publication date: June 20, 2013Applicant: UNIVERSITY OF SOUTH CAROLINAInventor: UNIVERSITY OF SOUTH CAROLINA
-
Publication number: 20130160153Abstract: Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin ? light chain variable domain.Type: ApplicationFiled: December 17, 2012Publication date: June 20, 2013Applicant: Regeneron Pharmaceuticals, Inc.Inventor: Regeneron Pharmaceuticals, Inc.
-
Publication number: 20130157312Abstract: The present invention relates to nucleic acid fragments and constructs comprising genomic nucleotide sequences, which are present upstream of Rb1 and p15C that are associated with intergenic transcription, for the production of a gene product of interest in a eukaryotic, preferably mammalian, host cell in the presence of a stringent selectable marker. The invention further relates to host cells comprising the nucleic acid constructs, to methods for generating the host cells and to methods for producing a gene product of interest using the host cells.Type: ApplicationFiled: June 15, 2011Publication date: June 20, 2013Inventors: Arie Pieter Otte, Michel Siep, John Antonius Verhess, Femke Hoeksema
-
Publication number: 20130160151Abstract: The present invention relates to the use of a transgenic non-human animal, such as a mouse, expressing a reporter gene detectable by a chromogenic, luminescent or fluorescent signal which identifies the cells that express Pw1, or of Pw1-expressing cells or tissues isolated therefrom, as a model for screening a candidate substance for its ability to stimulate adult stem cells, or for monitoring cell aging.Type: ApplicationFiled: July 6, 2011Publication date: June 20, 2013Applicant: Universite Pierre et Marie Curie (PARIS 6)Inventors: David Sassoon, Vanessa Besson, Giovanna Marazzi
-
Patent number: 8465976Abstract: The invention relates to the isolation and use of hematopoietic and embryonic stem cells. Additionally, the inventors identified the peritoneal cavity as a new source of hematopoietic stem cells. In one embodiment, the invention provides methods of isolating progenitor and/or stem cells from the peritoneal cavity. In another embodiment, the invention provides methods of transporting progenitor and/or stem cells from the peritoneal cavity to another organ. In another embodiment, the present invention provides methods of regenerating bioengineered tissues and/or reconstituting an hematopoietic system.Type: GrantFiled: February 12, 2008Date of Patent: June 18, 2013Assignee: Cedars-Sinai Medical CenterInventors: Behrooz Sharifi, Lai Wang, Prediman K. Shah
-
Publication number: 20130142792Abstract: Disclosed are fusion proteins comprising a RAGE polypeptide, wherein the RAGE polypeptide comprises a fragment of a mammalian wild type RAGE peptide and at least one point mutation in the RAGE polypeptide portion of the fusion protein relative to the wild type RAGE peptide. The point mutation may remove and/or alter a glycosylation site or an enzyme cleavage site. Also disclosed are nucleic acids encoding such proteins as well as methods of using such proteins for treating RAGE-mediated pathologies.Type: ApplicationFiled: October 19, 2010Publication date: June 6, 2013Inventors: Jeffrey C. Webster, Gregory T. Bleck, Madan Katragadda, Manoj Rajadhyaksha, Bernard N. Violand, Jo-Ann Wentland, Linda Marie Rothlein
-
Publication number: 20130143264Abstract: The present invention relates to purified and isolated DNA sequences having protein production increasing activity and more specifically to the use of matrix attachment regions (MARs) for increasing protein production activity in a eukaryotic cell. Also disclosed is a method for the identification of said active regions, in particular MAR nucleotide sequences, and the use of these characterized active MAR sequences in a new multiple transfection method.Type: ApplicationFiled: June 28, 2012Publication date: June 6, 2013Applicant: SELEXIS SAInventors: Mermod Nicolas, Pierre Alain Girod, Philipp Bucher, Duc-Quang Nguyen, David Calabrese, Damien Saugy, Stefania Puttini
-
Publication number: 20130130313Abstract: There are provided a DNA construct comprising a suppressor tRNA gene of a non-eukaryote containing no internal promoter functioning in a eukaryotic cell, and a eukaryotic or bacteriophage promoter linked at the 5? end of the tRNA gene, a method for synthesizing a suppressor tRNA by using the DNA construct, and a process for producing protein incorporating a non-natural amino acid by using the same.Type: ApplicationFiled: April 30, 2012Publication date: May 23, 2013Applicant: RIKENInventors: Shigeyuki YOKOYAMA, Kensaku Sakamoto, Nobumasa Hino, Takahito Mukai, Takatsugu Kobayashi
-
Publication number: 20130130388Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.Type: ApplicationFiled: December 19, 2012Publication date: May 23, 2013Applicant: Regeneron Pharmaceuticals, Inc.Inventor: Regeneron Pharmaceuticals, Inc.
-
Publication number: 20130130273Abstract: Disclosed is a novel method for detecting interactions of biomolecules. More particularly, the disclosed method includes (a) preparing a cell comprising (i) a first construct comprising a bait, a first labeling material and a translocation module; and (ii) a second construct comprising a prey and a second labeling material; (b) detecting the distribution of the first construct and the second construct in the cell. the present invention provides a method capable of detecting bindings and interactions occurring in a living cell in real time, and a method for screening a material that alters the binding and the interaction. The method of the present invention overcomes the disadvantages including inaccuracy and complexity of existing biomaterial interaction detection techniques. By labeling both constructs to promote accuracy, the present invention provides a novel real-time, antibody-free analysis.Type: ApplicationFiled: January 3, 2013Publication date: May 23, 2013Applicant: Korea Basic Science InstituteInventor: Korea Basic Science Institute
-
Publication number: 20130133092Abstract: The present invention relates to a method of sequence specific recombination of DNA in eukaryotic cells utilizing att sequences from the bacteriophage lambda. A particular embodiment of the invention relates to a method further comprising performing the sequence specific recombination of DNA with an Int and a Xis factor. The present invention further relates to vectors containing each of these sequences and their use as medicaments.Type: ApplicationFiled: November 1, 2012Publication date: May 23, 2013Inventor: Dr. Peter Droge
-
Publication number: 20130130248Abstract: The present disclosure provides variant Csy4 endoribonucleases, nucleic acids encoding the variant Csy4 endoribonucleases, and host cells genetically modified with the nucleic acids. The variant Csy4 endoribonucleases find use in a variety of applications, which are also provided. The present disclosure also provides methods of detecting a specific sequence in a target polyribonucleotide; and methods of regulating production of a target RNA in a eukaryotic cell.Type: ApplicationFiled: November 7, 2012Publication date: May 23, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
-
Publication number: 20130129761Abstract: Provided herein are influenza hemagglutinin stem domain polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use.Type: ApplicationFiled: March 30, 2011Publication date: May 23, 2013Applicant: Mount Sinai School of MedicineInventors: Adolfo Garcia-Sastre, Peter Palese, John Steel, Anice C. Lowen
-
Publication number: 20130122586Abstract: According to embodiments, a method of producing insulin-producing tissues (IPTs) by culturing comprises: preparing non-endocrinal epithelial cells (NEECs) and vascular endothelial cells (VECs), which have been isolated or originated from postnatal pancreata, preferably by capturing of NEECs by collagen; culturing in vitro the NEECs and the VECs at least partly separately from each other; and then generating in vitro a tissue complex (IPTs) that contains both the NEECs and the VECs. In another embodiment, the native islet cells are seeded on a monolayer of VECs that have preferably been separately cultured and purified. In a further embodiment, a method of enriching NEECs comprises: culturing NEECs adhering to a container or substrate; removing NEECs by treating with a tissue-dissociation enzyme to leave left-over cells (LOCs) still attached on the container or substrate; and culturing NEECs in a medium conditioned by, or in the presence of the LOCs.Type: ApplicationFiled: March 15, 2011Publication date: May 16, 2013Applicant: KYOTO UNIVERSITYInventors: Jun Kanamune, Yasuhiro Iwanaga, Shinji Uemoto, Yoshiya Kawaguchi
-
Publication number: 20130122004Abstract: The present disclosure is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The fusion polypeptides of the disclosure include FGF23 or an active fragment thereof. In one embodiment, the fusion polypeptide comprises (a) a polypeptide comprising fibroblast growth factor 23 (FGF23), or a functionally active variant or derivative thereof, wherein FGF23 has a mutation at one or more of the positions Q156, C206 and C244; and (b) either a modified Fc fragment having decreased affinity for Fc-gamma-receptor and/or increased serum half-life, or a polypeptide comprising at least one extracellular subdomain of a Klotho protein, or a functionally active variant or derivative thereof; and, optionally (c) a linker. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders.Type: ApplicationFiled: January 17, 2013Publication date: May 16, 2013Applicant: NOVARTIS AGInventor: Novartis AG
-
Patent number: 8440458Abstract: The invention relates to a process for the culturing of cells, preferably E1-immortalized HER cells, more preferably PER.C6 cells in a reactor in suspension in a cell culture medium, wherein the cells produce a biological substance, preferably an antibody, wherein at least one cell culture medium component is fed to the cell culture and wherein the cell culture comprising the cells, the biological substance and cell culture medium is circulated over a separation system and wherein the separation system separates the biological substance from substances having a lower molecular weight than the biological substance and wherein the biological substance is retained in or fed back into the reactor. Preferably part of the substances of lower molecular weight is continuously removed from the cell culture.Type: GrantFiled: February 15, 2012Date of Patent: May 14, 2013Assignee: DSM IP Assets B.V.Inventors: Gerben Meile Zijlstra, Robert Patrick Hoff, Jacob Schilder
-
Publication number: 20130117872Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a Group H nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.Type: ApplicationFiled: September 14, 2012Publication date: May 9, 2013Inventors: Subba Reddy PALLI, Mohan Basavaraju Kumar, Dean Ervin Cress, Ted Tsutomu Fujimoto
-
Publication number: 20130116165Abstract: The invention, in some aspects relates to synthetic, light-activated fusion proteins and their encoding polynucleotide molecules. In some aspects the invention additionally includes expression of the light-activated fusion proteins in cells and their use in methods such as therapeutic methods and candidate compound screening methods.Type: ApplicationFiled: September 27, 2012Publication date: May 9, 2013Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventor: Massachusetts Institute of Technology
-
Publication number: 20130115239Abstract: The present invention concerns an (adjuvant) treatment or prevention option for the treatment and prevention of prostate cancer. In particular, it pertains to the provision of recombinant, optimized PAP genes which are useful as DNA vaccines for the above treatment or prevention.Type: ApplicationFiled: November 25, 2010Publication date: May 9, 2013Applicant: UNIVERSITÄT KONSTANZInventors: Marcus Groettrup, Peter Oehlschlaeger
-
Publication number: 20130109090Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.Type: ApplicationFiled: October 5, 2012Publication date: May 2, 2013Applicant: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCHInventor: Whitehead Institute for Biomedical Research
-
Publication number: 20130111615Abstract: This invention provides RNA, oligoribonucleotide, and polyribonucleotide molecules comprising pseudouridine or a modified nucleoside, gene therapy vectors comprising same, methods of synthesizing same, and methods for gene replacement, gene therapy, gene transcription silencing, and the delivery of therapeutic proteins to tissue in vivo, comprising the molecules. The present invention also provides methods of reducing the immunogenicity of RNA, oligoribonucleotide, and polyribonucleotide molecules.Type: ApplicationFiled: August 14, 2012Publication date: May 2, 2013Inventors: Katalin Kariko, Drew Weissman
-
Publication number: 20130109087Abstract: The present invention provides a method for producing a transgenic (Tg) non-human animal capable of developing an enhanced humoral immune response against an antigen as compared to a non-transgenic control animal of the same species, comprising introducing into said non-human animal a genetic construct providing for enhanced MHC class I-related neonatal Fc receptor (FcRn) activity. Also provided a Tg non-human animal comprising a genetic construct providing for enhanced FcRn activity, as well as the use of such animal in a non-therapeutical method. Therapeutic genetic constructs and methods are also provided. The present invention further provides methods for producing immunoglobulins.Type: ApplicationFiled: October 10, 2012Publication date: May 2, 2013Applicants: EOTVOS LORAND UNIVERSITY, AGRICULTURAL BIOTECHNOLOGY CENTERInventors: AGRICULTURAL BIOTECHNOLOGY CENTER, Eotvos Lorand University
-
Publication number: 20130109089Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.Type: ApplicationFiled: October 5, 2012Publication date: May 2, 2013Applicant: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCHInventor: Whitehead Institute for Biomedical Research
-
Publication number: 20130102074Abstract: The invention provides methods for reprogramming somatic cells to generate multipotent or pluripotent cells. Such methods are useful for a variety of purposes, including treating or preventing a medical condition in an individual. The invention further provides methods for identifying an agent that reprograms somatic cells to a less differentiated state.Type: ApplicationFiled: October 5, 2012Publication date: April 25, 2013Applicant: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCHInventor: Whitehead Institute for Biomedical Research
-
Publication number: 20130102479Abstract: We provide for the use of Tbx3 (GenBank Accession Number: NM_005996.3 (SEQ ID NO. 1), NP_005987.3 (SEQ ID NO. 2), NM_016569.3 (SEQ ID NO. 3), NP_057653.3 (SEQ ID NO. 4)) in a method of enhancing or inducing pluripotency in a cell such as a somatic cell. We describe a method of reprogramming a cell, the method comprising modulating the expression and/or activity of Tbx3 in the cell. The cell may become a pluripotent cell such as a stem cell. We further describe a method of causing a cell such as a somatic cell to display one or more characteristics of a pluripotent cell, the method comprising modulating the expression and/or activity of Tbx3 in the cell. The method may further comprise modulating the expression and/or activity of one or more, a combination of or all of Oct4, Sox2 and Klf4 in the cell.Type: ApplicationFiled: November 18, 2010Publication date: April 25, 2013Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Bing Lim, Jianyong Han, Wai-Leong Tam
-
Publication number: 20130104253Abstract: Methods for de-differentiating or altering the life-span of desired “recipient” cells, e.g., human somatic cells, by the introduction of cytoplasm from a more primitive, less differentiated cell type, e.g., oocyte or blastomere are provided. These methods can be used to produce embryonic stem cells and to increase the efficiency of gene therapy by allowing for desired cells to be subjected to multiple genetic modifications without becoming senescent. Such cytoplasm may be fractionated and/or subjected to subtractive hybridization and the active materials (sufficient for de-differentiation) identified and produced by recombinant methods.Type: ApplicationFiled: September 14, 2012Publication date: April 25, 2013Inventor: Karen B. CHAPMAN
-
Publication number: 20130102028Abstract: The present invention relates to a transgenic fertilized egg in which expression constructs, excluding human expression constructs, are introduced, including: (a) a nucleotide sequence encoding hypoxia-inducible factor 2? (HIF-2?); and (b) a transcription-regulating sequence which is operatively linked to the nucleotide sequence, as well as to a transgenic animal model for arthritis obtained therefrom. A transgenic mouse transformed with a recombinant expression vector of the present invention may be very useful as a therapeutic model for arthritis, which may be used in studies on the cartilage degeneration process. In addition, the transgenic mouse of the present invention may be applied to a method for screening arthritis therapeutics.Type: ApplicationFiled: December 8, 2010Publication date: April 25, 2013Applicant: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Jang-Soo Chun, Si Young Yang
-
Publication number: 20130096058Abstract: The present invention provides Tenascin-3 FnIII domain-based multimeric scaffolds that specifically bind to TRAIL Receptor 2 (TRAIL R2), a cell membrane receptor involved in apoptosis. The invention further provides engineered variants with increased affinity for the target, increased stability, and reduced immunogenicity. Furthermore, the present invention is related to engineered multivalent scaffolds as prophylactic, diagnostic, or therapeutic agents, and their uses against diseases caused by cells expressing TRAIL R2, in particular to a therapeutic use against cancer.Type: ApplicationFiled: April 12, 2011Publication date: April 18, 2013Applicant: MedImmune, LLCInventors: Manuel Baca, Thomas Thisted, Jeffrey Swers, David Tice
-
Publication number: 20130095565Abstract: Targeting constructs and methods of using them are provided for differentiation-dependent modification of nucleic acid sequences in cells and in non-human animals. Targeting constructs comprising a promoter operably linked to a recombinase are provided, wherein the promoter drives transcription of the recombinase in an differentiated cell but not an undifferentiated cell. Promoters include Blimp1, Prm1, Gata6, Gata4, Igf2, Lhx2, Lhx5, and Pax3. Targeting constructs with a cassette flanked on both sides by recombinase sites can be removed using a recombinase gene operably linked to a 3?-UTR that comprises a recognition site for an miRNA that is transcribed in undifferentiated cells but not in differentiated cells. The constructs may be included in targeting vectors, and can be used to automatically modify or excise a selection cassette from an ES cell, a non-human embryo, or a non-human animal.Type: ApplicationFiled: December 3, 2012Publication date: April 18, 2013Applicant: Regeneron Pharmaceuticals, Inc.Inventor: Regeneron Pharmaceuticals, Inc.
-
Publication number: 20130096287Abstract: Mice having a restricted immunoglobulin heavy chain locus are provided, wherein the locus is characterized by a single polymorphic human VH gene segment, a plurality of human DH gene segments and a plurality of JH gene segments. Methods for making antibody sequences that bind an antigen (e.g., a viral antigen) are provided, comprising immunizing a mouse with an antigen of interest, wherein the mouse comprises a single human VH gene segment, a plurality of human DH gene segments and a plurality of JH gene segments, at the endogenous immunoglobulin heavy chain locus.Type: ApplicationFiled: October 17, 2012Publication date: April 18, 2013Applicant: Regeneron Pharmaceuticals, Inc.Inventor: Regeneron Pharmaceuticals, Inc.
-
Publication number: 20130097718Abstract: The invention provides methods of treating cancer using a Chd5 protein or an agonist thereof. Also provided are diagnostics, screening methods of cancer therapeutics, and cancer models useful for studying cancer biology and drug screening.Type: ApplicationFiled: July 6, 2012Publication date: April 18, 2013Applicant: Cold Spring Harbor LaboratoryInventors: Alea A. Mills, Anindya Bagchi, Cristian Constantin Papazoglu-Statescu
-
Publication number: 20130095569Abstract: The present invention provides pregnancy associated plasma protein A2 (PAPP-A2), its nucleotide and amino acid sequences antisense molecules to the nucleotide sequences which encode PAPP-A2, expression vectors for the production of purified PAPP-A2, antibodies capable of binding specifically to PAPP-A2, hybridization probes or oligonucleotides for the detection of PAPP-A2-encoding nucleotide sequences, genetically engineered host cells for the expression of PAPP-A2, and methods for screening for pathologies in pregnant and non-pregnant patients. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of PAPP-A2, are also described.Type: ApplicationFiled: September 24, 2012Publication date: April 18, 2013Inventors: Claus Oxvig, Michael Toft Overgaard
-
Patent number: 8420306Abstract: This application relates to a newly identified animal cell structure, the midbody scar. This structure is a remnant of the midbody that is retained by one daughter cell following cytokinesis and persists through multiple subsequent cell cycles. The midbody scar can be useful as a marker of dividing cells or of a cell's replicative age.Type: GrantFiled: March 22, 2010Date of Patent: April 16, 2013Assignee: University of MassachusettsInventors: Stephen J. Doxsey, Chun-Ting Chen
-
Publication number: 20130078223Abstract: The present invention provides pluripotent stem cell like (PSCL) cells or clones, a culture medium therefore, and a supernatant thereof, and methods of making and using the same.Type: ApplicationFiled: November 14, 2012Publication date: March 28, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: The Regents of the University of California
-
Publication number: 20130079881Abstract: The present invention relates to a tissue-engineered intervertebral disc (IVD) suitable for total disc replacement in a mammal and methods of fabrication. The IVD comprises a nucleus pulposus structure comprising a first population of living cells that secrete a hydrophilic protein and an annulus fibrosis structure surrounding and in contact with the nucleus pulposus structure, the annulus fibrosis structure comprising a second population of living cells and type I collagen. The collagen fibrils in the annulus fibrosis structure are circumferentially aligned around the nucleus pulposus region due to cell-mediated contraction in the annulus fibrosis structure. Also disclosed are methods of fabricating tissue-engineered intervertebral discs.Type: ApplicationFiled: May 5, 2010Publication date: March 28, 2013Applicant: CORNELL UNIVERSITYInventors: Lawrence J. Bonassar, Roger Hartl, Robert D. Bowles, Harry H. Gebhard